GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
ClinicalTrials.gov · NCT04731272 · Registry updated: 2026-05-18
- Condition / research focus
- Cystic Fibrosis; Pancreatic Insufficiency; Abnormal Glucose Tolerance; Diabetes
- Sponsor
- University of Pennsylvania
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2021-07-16. Completion: 2028-06-30 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Dulaglutide 0.75Mg/0.5Ml Inj Pen (drug)
Where the study takes place — 2 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Children's Hospital of Colorado
Aurora, Colorado, United States
Site recruitment: Recruiting - University of Pennsylvania
Philadelphia, Pennsylvania, United States
Site recruitment: Recruiting